K2 Principal Fund L.P. reduced its position in Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) by 71.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,836 shares of the company’s stock after selling 40,030 shares during the quarter. K2 Principal Fund L.P.’s holdings […]
Lumos Pharma (NASDAQ:LUMO – Get Rating) and IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Risk & Volatility Lumos Pharma has a beta of […]
Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) – Equities research analysts at HC Wainwright upped their Q2 2023 EPS estimates for shares of Lumos Pharma in a research report issued on Thursday, May 4th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($0.99) per share for the quarter, up […]
Lumos Pharma (NASDAQ:LUMO – Get Rating) will be issuing its quarterly earnings data after the market closes on Wednesday, May 3rd. Analysts expect the company to announce earnings of ($1.12) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link. Lumos Pharma (NASDAQ:LUMO – […]
Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics.